H.C. Wainwright analyst Debjit Chattopadhyay says Sarepta Therapeutics' (SRPT) lead in developing a gene therapy for Duchenne muscular dystrophy is potentially solidified after Solid Biosciences' (SLDB) Phase 1/2 clinical program was placed on clinical hold. Based on the differences between Sarepta's and Solid's vectors and the evolving safety profiles of the two competing approaches, the analyst would be a buyer of Sarepta's stock "in the event of any collateral damage stemming from the Solid Biosciences clinical hold." He keeps a Buy rating on Sarepta shares with a $92 price target.